

**Phase I Clinical Trial Results of TAK-102 (NIB102), a CAR-T Cell Therapy Incorporating
Our Proprietary PRIME Technology, Published in *Cancer Immunology Research*
— Findings Support a Manageable Safety Profile and Provide Early Evidence of
Biological Activity in Solid Tumors —**

Noile-Immune Biotech Inc. (hereinafter “the Company”) announces that the results of the first-in-human, Phase I dose-escalation clinical trial of TAK-102, conducted by Takeda Pharmaceutical Company Limited (hereinafter “Takeda”), to which our proprietary drug development pipeline NIB102 was previously licensed, have been published in the scientific journal, *Cancer Immunology Research*. The rights to NIB102 have since been returned by Takeda and are currently held by the Company.

NIB102 is a Glypican-3 (GPC3)-targeted CAR-T cell therapy incorporating the Company’s proprietary, innovative PRIME (Proliferation-Inducing Migration-Enhancing) technology, which is designed to enhance the therapeutic efficacy of immune cell therapies (see page 34 of the “Business plan and growth potential Matters” of the Company^{Note 1)}).

In the first-in-human, Phase I dose-escalation clinical trial conducted by Takeda under the development code TAK-102, a total of 11 patients received the investigational CAR-T cell therapy. The findings supported a manageable safety profile and provided early evidence of biological activity in solid tumors, including tumor shrinkage, stable disease, and increased infiltration of CD8-positive T cells into tumor tissue.

These findings have been published in the scientific journal, *Cancer Immunology Research*, as detailed below.

- Title: Autologous Glypican-3–Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102
- Journal: *Cancer Immunology Research*
- DOI: 10.1158/2326-6066.CIR-25-0855
- Pubmed URL: <https://pubmed.ncbi.nlm.nih.gov/42709571/>

Note 1) ”[Business plan and growth potential Matters](#)”

【Noile-Immune Biotech Inc.】

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune



cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit <https://www.noile-immune.com/en/>

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

pr@noile-immune.com